Core Viewpoint - The article discusses a study comparing the effectiveness of three NAD+ supplements: Nicotinamide (Nam), Nicotinamide Riboside (NR), and Nicotinamide Mononucleotide (NMN), highlighting that NR and NMN significantly increase NAD+ levels in humans, while Nam does not show a significant difference compared to a placebo [2][3][9]. Group 1: Study Overview - The study was conducted by Nestlé Health Science and published in Nature Metabolism, focusing on the differential impacts of the three NAD+ boosters on human circulatory NAD+ levels and microbial metabolism [2][3][9]. - A total of 65 healthy participants were randomly assigned to four groups, receiving either NR (1000mg), NMN (1000mg), Nam (500mg), or a placebo for 14 days [9]. Group 2: Results - NR and NMN resulted in a doubling of NAD+ levels in participants, with increases of 49.4μM and 43.1μM respectively, while the Nam group showed no significant difference compared to the placebo group [9]. - The study indicates that the effectiveness of NR and NMN is due to their conversion to nicotinic acid (NA) by gut microbiota, leading to a sustained increase in NAD+ levels [11][12]. Group 3: Mechanism of Action - NR and NMN require gut microbiota for their metabolism, which ensures a gradual and stable increase in NAD+ levels, while Nam is rapidly absorbed, leading to transient effects [11][12]. - The research also highlights that NR and NMN not only enhance NAD+ levels but also promote the growth of beneficial gut bacteria and increase the production of short-chain fatty acids (SCFAs), suggesting dual health benefits [15]. Group 4: Implications for Supplementation - The findings suggest that NR and NMN are superior choices for NAD+ supplementation, emphasizing the need for long-term use to achieve stable effects [15]. - The study underscores the importance of gut microbiota in nutrient metabolism and suggests that personalized supplementation strategies for specific populations, such as the elderly or those with gut dysbiosis, warrant further exploration [15].

Core Viewpoint - The study highlights the role of interferon-induced CD8+ T cell senescence as a driving factor for immune therapy resistance in early triple-negative breast cancer (TNBC), suggesting that nicotinamide mononucleotide (NMN) treatment may restore T cell function and enhance the benefits of immune checkpoint blockade therapy [4][5][8]. Group 1: TNBC Characteristics and Treatment Challenges - TNBC is defined by the absence or low expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), characterized by higher recurrence rates and shorter overall survival in patients [3]. - Chemotherapy remains the primary systemic treatment for TNBC due to the lack of specific therapeutic targets, but its efficacy is limited to a subset of patients [3]. Group 2: Research Findings on T Cell Senescence - A study published in Science Translational Medicine found that interferon (IFN)-induced CD8+ T cells reduce the efficacy of anti-PD-1 immunotherapy in early TNBC patients and preclinical models [4][5]. - The research identified a group of enriched IFN-induced CD8+ T cells in early TNBC samples that predict non-responsiveness to immunotherapy, driven by HLA-DR+ monocyte-derived IFN leading to T cell senescence [6]. Group 3: Potential Therapeutic Strategies - Treatment with NMN, a precursor of NAD+, was shown to restore the function of senescent CD8+ T cells and enhance the effects of immunotherapy in both patient-derived organoid-T cell co-cultures and mouse models [5][6][8]. - The findings suggest that targeting T cell senescence could be a promising strategy to improve immunotherapy outcomes in early TNBC [8].

Core Viewpoint - The recent study challenges the belief that NAD+ depletion significantly impacts muscle function and accelerates aging, suggesting that muscle health may not be as dependent on NAD levels as previously thought [2][5][11]. Group 1: Study Findings - The study utilized an inducible skeletal muscle-specific Nampt gene knockout (iSMNKO) mouse model, resulting in an 85% reduction in NAD+ levels without affecting muscle mass, integrity, contraction strength, or exercise performance [2][9]. - Even with lifelong NAD+ depletion, the mice did not exhibit accelerated muscle aging or systemic metabolic impairment [8][9]. - The research indicates that skeletal muscle can tolerate significant NAD+ depletion without losing functionality or accelerating aging, contradicting the common belief that NAD+ reduction is a primary driver of muscle aging and weakness [5][11]. Group 2: Implications for NAD+ Supplementation - The findings raise questions about the efficacy of NAD+ supplementation as an anti-aging strategy, suggesting that it may be a waste of resources [5][11]. - The study's leader emphasized that the results challenge the notion that reduced NAD+ levels are a major factor in muscle aging and weakness [5][11]. - The research highlights the need for further investigation into the extent to which NAD+ reduction affects mitochondrial function and the aging process [6][11].